Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis (NCT00173706) | Clinical Trial Compass
UnknownPhase 4
Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis
Taiwan40 participantsStarted 2004-10
Plain-language summary
This is a study designed to test the hypothesis that treatment with L-carnitine will improve the quality of life and some specific symptoms and signs in patients with renal failure submitted to hemodialysis.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female adults over 18 years of age
✓. On hemodialysis for at least one year
✓. Interdialysis weight gain \< 5%
✓. Bicarbonate dialysis 3 times per week
✓. Modality of dialysis unchanged for 3 months prior to entry into the study (concerning dialysis-time and mode: bicarbonate, acetate dialysis)
✓. Have one of the following symptoms and signs that have not responded to diet or pharmacological intervention:
✓. persistent weakness affecting daily life
✓. malnutrition
Exclusion criteria
✕. Severe uncontrolled hypertension (systolic \> 170; diastolic \> 115) outside of dialysis
✕. Some patients have echocardiogram (ECHO) defined chronic heart failure. Patients with New York Heart Association (NYHA) class II and class III can be admitted. Patients with class IV must be excluded. Some patients have angina. Patients with stable effort angina well controlled by treatment can be recruited. Absolute exclusion for angina at rest.
✕. Major hepatic diseases - chronic active (aggressive) hepatitis or cirrhosis